Echo Therapeutics Appoints Robert Doman to Board of Directors

        Echo Therapeutics Appoints Robert Doman to Board of Directors

PR Newswire

PHILADELPHIA, March 13, 2013

PHILADELPHIA, March 13, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® CGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system,
today announced the appointment of Robert F. Doman to its Board of Directors.


Mr. Doman brings to Echo Therapeutics over 30 years of executive level,
international and domestic management, business development, sales and
marketing, product development and strategic planning experience with specific
concentrations in medical devices and pharmaceuticals.

"With the anticipated near-term commercialization of our Symphony CGM System
and our continued positive momentum setting the pace for an exciting future,
we are very pleased to have Bob join our Board of Directors. Bob brings to the
Board valuable hands-on experience and innovative ideas," commented Patrick T.
Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.
"Bob's extensive strategic business planning and execution experience will
enable him to make a significant contribution to the future success of Echo."

Most recently, Mr. Doman served as President and Chief Executive Officer of
publicly-traded DUSA Pharmaceuticals, Inc., which he joined in 2005. Under
his leadership, the company strengthened its IP position, expanded its sales
and marketing capabilities and repositioned its products in the marketplace.
In 2012, Mr. Doman completed the successful sale of the company to Sun
Pharmaceuticals in a $230 million transaction. From 2000 to 2004, Mr. Doman
served as President of Leach Technology Group, the medical electronic device,
design, product development and contract manufacturing services division of
Leach Holding Corporation, which was sold to Esterline Technologies in 2004.
He served as President of Device Product Development of West Pharmaceutical
Services from 1999 to 2000. Prior to that, Mr. Doman held marketing and
business development positions at the Convatec division of Bristol-Myers
Squibb and Critikon, Inc., a Johnson & Johnson company. He earned his
Bachelor's degree from Saint Joseph's University.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony CGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony CGM and Prelude SkinPrep Systems, Echo's ability to secure
additional commercial partnering arrangements, risks and uncertainties
relating to Echo's and its partners' ability to develop, market and sell
diagnostic and transdermal drug delivery products based on its skin permeation
platform technologies, including the Symphony CGM and Prelude SkinPrep
Systems, the availability of substantial additional equity or debt capital to
support its research, development and product commercialization activities,
and the success of its research, development, regulatory approval, marketing
and distribution plans and strategies, including those plans and strategies
related to its Symphony CGM and Prelude SkinPrep Systems. These and other
risks and uncertainties are identified and described in more detail in Echo's
filings with the Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the year ended December 31,
2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K.
Echo undertakes no obligation to publicly update or revise any forward-looking

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104

Connect With Us:
- Visit our website at
- Follow us on Twitter at
- Join us on Facebook at

SOURCE Echo Therapeutics, Inc.

Press spacebar to pause and continue. Press esc to stop.